Nkarta: at least as good as Fate, at a tenth of the price
After a long wait, investors at last have early evidence that Nkarta’s Car-NK cells work – with a relatively clean safety profile to boot.
Key data reveals for the small players
Praxis, Proqr and Nordic Nanovector are awaiting important data.
Roche U-turns and Adaptimmune wins
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
Fate delivers, up to a point
The first human data from the Car-NK project FT596 are impressive – but not impressive enough for a company worth $9bn.
Fate looks to justify its $9bn valuation
The glacial development of Fate’s anti-CD19 Car-NK therapy FT596 could yield real data at last.
Asco 2021 movers – PDS wins, but big pharma reigns
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Can we freeze them? Yes we can, says Nkarta
The company is now in the clinic, claiming to have cleared one of the biggest hurdles blocking development of an NK cell therapy.
